CHECK TREATMENT ELIGIBILITY

Enter your patient's mutations below

TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data. 

Eligible

Please check to see if the mutation was entered correctly.

Results

Learn how to enter 2 or more mutations